Last Published 05.01.2026 Effective Date: 05.01.2026 This policy addresses cardiac event monitoring, including ambulatory event monitoring, outpatient cardiac telemetry, and implantable loop recorder
Ipamorelin, a new potent growth hormone secretagogue, reverses the suppressive effects of glucocorticoids on growth and IGF-I in a rat model
Currently, many clinical practice guidelines, including the consensus guideline of the American Diabetes Association and the European Association for the Study of Diabetes, recommend glucagon-like peptide-1 receptor agonist (GLP-1RA) as the first-line injectable agent ahead of basal insulin for most patients with T2DM ( So far, two different products containing fixed-ratio combinations (FRCs) of basal insulin and GLP-1RA were approved by the US Food and Drug Administration and European Medicines Agency: IGlarLixi, which is a combo of insulin glargine and lixisenatide, and IDegLira, which is a combo of insulin degludec and liraglutide ( Based on these backgrounds, this study aimed to evaluate the overall effect of adding basal insulin on persisting GLP-1RA treatment
Accelerated healing and recovery: BPC157 is one of the most studied peptides for injury recovery
